The fresh capital will accelerate the expansion of Debut's AI-based ingredient discovery platform and scale its presence in Asia.WHO: Debut is a vertically integrated synthetic biology company spearheading the creation of innovative and novel high-performing active ingredients. The company specializes in scientifically discovered, clinically proven, and inherently sustainable ingredients that provide maximum efficacy. WHY: The investment will help accelerate the expansion of its proprietary, AI-based ingredient discovery platform to advance skin longevity innovation and scale its formulation business in the US and Asia. The funding will propel the discovery of next-generation ingredients that target the 14 hallmarks of aging, and empower Debut's global beauty partners to innovate with peak-performing biotech ingredients and formulations married to novel claims. It will also enable beauty brands at all stages of growth to outsource their formulation innovation in record time, at scale, and without the heavy upfront R&D expense associated with biotech.IN THEIR OWN WORDS: "Debut is laser-focused on staying at the forefront of skincare innovation and bringing cutting-edge biotech to every beauty brand with the highest-performing and most differentiated ingredients. This funding will enhance our ability to screen upward of 50 billion ingredients to explore the 99.999 percent of unknown molecules that can optimize skin health and make skin longevity a reality," said Joshua Britton, PhD, founder and CEO of Debut.